MacroGenics board member Karen Ferrante to resign effective September 1, 2026
Ferrante notified the board of her departure on July 1, 2026, with the company saying the move was unrelated to any dispute over its operations.
MacroGenics, Inc. disclosed in an 8-K filing dated July 8, 2026 that Karen Ferrante, M.D. notified the company's board of directors on July 1, 2026 of her decision to resign from the board, with the resignation effective September 1, 2026.1
The filing states that the decision was made for personal reasons and did not stem from any disagreement with the company or any issue tied to its operations, policies, or practices.1 The company thanked Dr. Ferrante for her contributions.1
The filing was signed by Jeffrey Peters, MacroGenics' Senior Vice President, General Counsel and Corporate Secretary. No successor to Dr. Ferrante's board seat was named in the filing, and no other changes to the board or executive team were disclosed.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.